Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: Primary results of the PREvention of thromboemolic events-European Registry in Atrial Fibrillation (PREFER in AF)

Europace

Volumn 16, Issue 1, 2014, Pages 6-14

  Kirchhof, Paulus ^a,b   Ammentorp, Bettina ^c   Darius, Harald ^d   De Caterina, Raffaele ^e   Le Heuzey, Jean Yves ^f   Schilling, Richard John ^g   Schmitt, Josef ^c   Zamorano, Jose Luis ^h  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c DAIICHI SANKYO CO   (Japan)

^d VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^e FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g ST THOMAS HOSPITAL   (United Kingdom)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Adherence to guidelines; Antiarrhythmic drugs; Anticoagulation; Atrial fibrillation; Catheter ablation; Guidelines; Management; Rate control; Registry; Rhythm control; Stroke

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMIODARONE; APIXABAN; CLOPIDOGREL; DABIGATRAN; DRONEDARONE; FLECAINIDE; FLUINDIONE; PHENPROCOUMON; PRASUGREL; PROPAFENONE; RIVAROXABAN; SOTALOL; TICAGRELOR; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CARDIOVERSION; CATHETER ABLATION; CONTROLLED STUDY; EUROPE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART RATE; HEART RHYTHM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLICATION; REGISTER; SINUS RHYTHM;

ADHERENCE TO GUIDELINES; ANTIARRHYTHMIC DRUGS; ANTICOAGULATION; ATRIAL FIBRILLATION; CATHETER ABLATION; GUIDELINES; MANAGEMENT; RATE CONTROL; REGISTRY; RHYTHM CONTROL; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOLOGY; CAUSALITY; COMORBIDITY; EUROPE; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; REGISTRIES; THROMBOEMBOLISM; VITAMIN K;

EID: 84891353605     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut263     Document Type: Article

References (23)

1. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53.
2. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110:1042-6.
3. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2012;14:8-27.
4. Kirchhof P, Curtis AB, Skanes AC, Gillis AM, Samuel Wann L, John Camm A. Atrial fibrillation guidelines across the Atlantic:acomparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association Of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 2013.
5. Bo S, Valpreda S, Scaglione L, Boscolo D, Piobbici M, Bo M et al. Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study. BMC Public Health 2007;7:203.
6. Zimetbaum P, Reynolds MR, Ho KK, Gaziano T, McDonald MJ, McClennen S et al. Impact of a practice guideline for patients with atrial fibrillation on medical resource utilization and costs. Am J Cardiol 2003;92:677-81.
7. Frykman V, Beerman B, Ryden L, Rosenqvist M. Management ofatrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J 2001;22:1954-9.
8. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
9. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC et al. Outcome parameters for trials inatrialfibrillation: recommendations from aconsensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 2007;9:1006-23.
10. Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J 2007;153:1006-12.
11. Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A et al. Impact of the type of centreonmanagement of AFpatients: surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost 2011;105:1010-23.
12. Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol 2011;100:897-905.
13. Bosch RF, Kirch W, Theuer JD, Pittrow D, Kohlhaussen A, Willich SN et al. Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: prospective non-interventional study. Int J Cardiol 2012.
14. Camm AJ, Breithardt G, Crijns H, Dorian P, Kowey P, Le Heuzey JY et al. Real-life observations of clinical outcomes with rhythm-and rate-control therapies for atrial fibrillation RECORDAF (Registry on cardiac rhythm disorders assessing the control of atrial fibrillation). J Am Coll Cardiol 2011;58:493-501.
15. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW et al. Atrial fibrillation management: a prospective survey in ESC member countries: the euro heart survey on atrial fibrillation. Eur Heart J 2005;26:2422-34.
16. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof Pet al. The Registry of the German Competence NETwork on Atrial Fibrillation: Patient characteristics and initial management. Europace 2009;11:423-34.
17. Lip G. EUR Observational research programme: atrial fibrillation general registry pilot phase. Eur H J 2013;34:794.
18. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ et al. Progression fromparoxysmaltopersistent atrialfibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010;55:725-31.
19. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL et al. Long-term progression and outcomes with aginginpatients with lone atrialfibrillation:a30-year follow-up study. Circulation 2007;115:3050-6.
20. Zoni-Berisso M, Filippi A, Landolina M, Brignoli O, D'Ambrosio G, Maglia Get al. Frequency, patient characteristics, treatment strategies, and resource usage of atrialfib-rillation (from the Italian Surveyof Atrial Fibrillation Management [ISAF] study).Am J Cardiol 2013;111:705-11.
21. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S et al. Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. PLoS ONE 2013;8:e63479.
22. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen Jet al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124.
23. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-73.